Management of HIV infection during pregnancy

Current Opinion in Obstetrics and Gynecology

Volumn 12, Issue 5, 2000, Pages 357-367

  McGowan, Joseph P ^a,b   Shah, Sanjiv S ^a,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b BRONX LEBANON HOSPITAL CENTER   (United States)

^c BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

DISEASE TRANSMISSION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; REVIEW; RISK FACTOR;

ANTI-HIV AGENTS; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK FACTORS;

EID: 0034302840     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200010000-00004     Document Type: Article

References (56)

1. Centers for Disease Control and Prevention. Critical need to pay attention to HIV prevention for women: minority and young women bear greatest burden. CDC Update 1998; 1-4.
2. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331:1173-1180.
3. US Public Health Service Perinatal HIV Guidelines Working Group. US Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States [web page] 2000; http://hivatis.org/guidelines/perinatal/PerinatalFeb2500.pdf. [accessed 25 June 2000]. These guidelines provide the latest recommendations by a panel of experts for the use of ART in HIV-infected pregnant women. Four case scenarios with various treatment strategies are discussed.
4. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000; 283:381-390. This consensus statement outlines the state of the art management of HIV infection with ART.
5. Mofenson LM. Interaction between timing of perinatal human immunodeficiency virus infection and the design of preventive and therapeutic interventions. Acta Paediatr Suppl 1997; 421:1-9.
6. Shearer WT, Langston C, Lewis DE, et al. Early spontaneous abortions and fetal thymic abnormalities in maternal-to-fetal HIV infection. Acta Paediatr Suppl 1997; 421:60-64.
7. Phuapradit W, Panburana P, Jaovisidha A, et al. Maternal viral load and vertical transmission of HIV-1 in mid-trimester gestation. AIDS 1999; 13:1927-1931.
8. Stringer JSA, Vermund SH. Prevention of mother-to-child transmission of HIV-1. Curr Opin Obstet Gynecol 1999; 11:427-434.
9. Chouquet C, Burgard M, Richardson S, et al. Timing of mother-to-child HIV-1 transmission and diagnosis of infection based on polymerase chain reaction in the neonatal period by a non-parametric method. AIDS 1997; 11:1183-1184.
10. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1. N Engl J Med 1999;340:977-987. This meta-analysis of 15 prospective cohort studies examined the impact of elective CS with and without zidovudine use in preventing vertical transmission.
11. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N Engl J Med 1999; 341:385-393. This study emphasized maternal HIV-1 VL as the most important predictor for perinatal transmission.
12. Dickover RE, Garratty E, Herman SA, et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. JAMA 1996; 275:599-605.
13. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med 1999; 341:394-402. Maternal HIV-1 plasma VL was found to correlate strongly with vertical transmission. No transmission was documented in mothers with VLs below 1000 copies/ml at the time of delivery.
14. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996; 335:1621-1629.
15. Kuhn L, Steketee RW, Weedon J, et al. Distinct risk factors for intrauterine and intrapartum human immunodeficiency virus transmission and consequences for disease progression in infected children. J Infect Dis 1999; 179:52-58.
16. Landesman SH, Kalish LA, Burns DN, et al. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. N Engl J Med 1996; 334:1617-1623.
17. Van Dyke RB, Korber BT, Popek E, et al. The ariel project: a prospective cohort study of maternal-child transmission of human immunodeficiency virus type 1 in the era of maternal antiretroviral therapy. J Infect Dis 1999; 179:319-328.
18. Wabwire-Mangen F, Gray RH, Mmiro FA, et al. Placental membrane inflammation and risks of maternal-to-child transmission of HIV-1 in Uganda. J Acquir Immun Defic Syndr 1999; 22:379-385.
19. Chuachoowong R, Shaffer N, Siriwasin W, et al. Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. J Infect Dis 2000; 181:99-106. Cervicovaginal lavage HIV RNA level was found to be an independent risk factor for perinatal transmission. Suppression of cervicovaginal lavage HIV RNA levels by zidovudine reduced vertical transmission.
20. The European Mode of Delivery Collaboration. Elective caesarian-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999; 353:1035-1039. Elective CS was found to reduce vertical transmission, but benefit was diminished by the use of ART.
21. Semprini AE, Castagna C, Ravizza M, et al. The incidence of complications after caesarian section in 156 HIV-positive women. AIDS 1995; 9:913-917.
22. Nduati R, John G, Mbori-Ngacha D, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 2000; 283:1167-1174. This paper conclusively establishes breastfeeding as the major mode of postpartum HIV transmission. Use of formula feeds resulted in less HIV transmission to newborns, but no difference in mortality was observed.
23. Kreiss J. Breast feeding and vertical transmission of HIV-1. Acta Paediatr Suppl 1997; 421:113-117.
24. Dunn DT, Newell ML, Ades AE, Peckham CS. Risk of human immuno deficiency virus type 1 transmission through breast-feeding. Lancet 1992; 340:585-588.
25. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382:722-725.
26. Moore JP, Trkola A, Dragic T. Co-receptors for HIV-1 entry. Curr Opin Immunol 1997; 9:551-562.
27. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 co-receptor accounts for resistance for some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367-377.
28. Philpott S, Burger H, Charbonneau T, et al. CCR5 genotype and resistance to vertical transmission of HIV-1. J Acquir Immun Defic Syndr 1999; 21:189-193. Infants who were homozygous for a mutated HIV coreceptor were protected from vertical transmission from their HIV-infected mothers.
29. Kostrikis LG, Neumann AU, Thomson B, et al. A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type 1 to African-American infants. J Virol 1999; 73:10264-10271.
30. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet 1999; 353:773-780.
31. Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet 1999; 353:781-785.
32. Dabis F, Msellati P, Meda N, et al. 6-month efficacy, tolerence, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet 1999; 353:786-792.
33. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795-802. Intrapartum use of nevirapine was found to be superior to zidovudine for the prevention of vertical transmission. Nevirapine was less costly and easier to administer.
34. Saba J. The results of the PETRA intervention trial to prevent perinatal transmission in sub-Saharan Africa [web page]. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, January 31-February 4 1999; http://www.retroconference.org/99/lect_symposia/sym_session8.html. [Accessed 28 June 2000]
35. McGowan JP, Crane M, Wiznia AA, Blum S. Combination antiretroviral therapy in human immunodeficiency virus-infected pregnant women. Obstet Gynecol 1999; 94:641-646. This paper demonstrates the effectiveness and short-term safety of potent ART for the prevention of perinatal HIV transmission in patients with advanced HIV infection and extensive prior antiretroviral use.
36. Morris A, Zorrilla C, Vajaranant M, et al. A review of protease inhibitor use in 89 pregnancies [abstract 686]. In: Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4 1999; Chicago, Illinois, USA. 1999, Foundation for Retrovirology and Human Health (Alexandria, VA). p. 197.
37. Shapiro D, Tuomala R, Samelson R, et al. Antepartum antiretroviral therapy and pregnancy outcomes in 462 HIV-infected women in 1998-1999 [abstract 664]. In: Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2 2000; San Francisco, California, USA. 2000, Foundation for Retrovirology and Human Health (Alexandria, VA). p. 199 Combination ART was superior to zidovudine monotherapy in reducing vertical HIV transmission in this large retrospective study.
38. Cooper ER, Charurat M, Burns D, et al. Trends in antiretroviral therapy and mother-infant transmission of HIV. J Acquir Immunodefic Syndr 2000; 24:45-47. This paper presents an analysis of ART use in pregnancy from 1990 to 1998 in over 1200 mother-infant pairs. There was no documented transmission in 70 mothers treated with protease inhibitor-containing regimens.
39. Clarke SM, Mulcahy F, Healy CM, et al. The efficacy and tolerability of combination antiretroviral therapy in pregnancy: infant and maternal outcome. Int J STD AIDS 2000; 11:220-223. Combination therapy effectively reduced maternal VL to below the level of detection in 76% of patients. Nevirapine was used successfully in six out of 11 mothers to intensify nonsuppressive therapy at 38 weeks of gestation.
40. US Public Health Service Perinatal HIV Guidelines Working Group. US Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Wkly Rep 1998; 47(RR-2):1-30.
41. Stiehm ER, Lambert JS, Mofenson LM, et al. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185. J Infect Dis 1999; 179:567-575.
42. Wade NA, Birkhead GS, Simonds RJ. Short courses of zidovudine and perinatal transmission of HIV. N Engl J Med 1999; 340:1042-1043. This retrospective analysis demonstrated the effectiveness of abbreviated courses of zidovudine to prevent infection in the newborn.
43. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposures. N Engl J Med 1997; 337:1485-1490.
44. Dickover R, Garratty E, Plaeger S, Bryson Y. Perinatal transmission of major, minor, and multiple HIV-1 strains in utero and intrapartum [abstract 181]. In: Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2 2000; San Francisco, California, USA; Foundation for Retrovirology and Human Health (Alexandria, VA)p. 109. 2000. This study described the different selective pressures involved at various times during pregnancy that may determine the type and diversity of HIV strains transmitted from mother to child.
45. Frenkel LM, Wagner LE, Demeter LM, et al. Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1. Clin Infect Dis 1995; 20:1321-1326.
46. Clarke JR, Braganza R, Mirza A, et al. Rapid development of genotypic resistance to lamivudine when combined with zidovudine in pregnancy. J Med Virol 1999; 59:364-368. Regimens that incompletely suppress HIV in the mother may lead to antiretroviral resistance and may compromise future options.
47. Musoke P, Quay LA, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999; 13:479-486.
48. Becker-Pergola G, Guay LA, Mmiro FA, et al. Selection of the K103N nevirapine resistance mutation in Ugandan women receiving NVP prophylaxis to prevent HIV-1 vertical transmission (HIVNET-006) [abstract 658]. In: Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2 2000; San Francisco, California, USA. 2000, Foundation for Retrovirology and Human Health (Alexandria, VA). p. 198. Single-dose nevirapine monotherapy used peripartum led to the rapid development of resistance in over 20% of pregnant women.
49. Anonymous. The antiretroviral therapy pregnancy registry interim report: July 31, 1999. Wilmington, NC: The Antiretroviral Pregnancy Registry, PharmaResearch; 1999. This is a report from a voluntary registry that collects and analyzes outcomes of antiretroviral use during pregnancy.
50. Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. AIDS 1998; 12:F241-F247.
51. + cell counts and possibly protease inhibitor use.
52. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354:1084-1089.
53. McIntosh K. Mitochondrial toxicity of perinatally administered zidovudine [abstract S14]. In: Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2 2000; San Francisco, California, USA. 2000 Foundation for Retrovirology and Human Health (Alexandria, VA). p. 242. This retrospective review of over 20000 uninfected offspring of HIV-infected mothers who were perinatally exposed to ART failed to demonstrate deaths attributable to mitochondrial toxicity.
54. Hirsch MS, Brun-Venzinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection. JAMA 2000; 283:2417-2426. These guidelines recommend resistance testing in HIV-infected pregnant women with VLs over 1000 copies/ml.
55. Fischl M, Rodriguez A, Scerpella E, et al. Impact of directly observed therapy on outcomes in HIV clinical trials [abstract 71]. In: Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2 2000; San Francisco, California, USA. 2000 Foundation for Retrovirology and Human Health (Alexandria, VA). p. 89.
56. Shapiro DE, Sperling RS, Mandelbrot L, et al. Risk factors for perinatal human immunodeficiency virus transmission in patients receiving zidovudine prophylaxis. Obstet Gynecol 1999; 94:897-908. This analysis of PACTG 076 data showed that an elevated maternal weight decreased the effectiveness of zidovudine for prophylaxis of vertical transmission.